Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog
Xuanyan Xu

Xuanyan Xu

Sr. Marketing Manager, Life Sciences Audience at Elsevier

Connect with Xuanyan Xu on LinkedIn
Follow Xuanyan Xu on Twitter
Website:

About the author: Seeing academic discoveries translated into life-changing applications is exciting--and, even more so, being a part of it. As a senior marketing manager for Life Sciences Audience, I bring a strong understanding of pharmaceutical industry needs, advancing technologies and customer insights to drive the product go-to-market strategy, planning and execution. Everything I write about here is geared towards issues that I deeply care about: open innovation, emerging approaches in data science and the evolving regulatory framework. Feel free to reach out to me about these topics. It is my desire to deliver my understanding and knowledge back to our communities.

Posts by Xuanyan Xu

Model-based Strategy to Guide the Choice of Clinical Doses for ADC

Posted on October 14th, 2020 in Pharma R&D

Chemotherapy has been a powerful method for fighting cancer for decades. One of the most effective therapies available, it is also known for weakening the patient and causing harsh side effects like pain, nausea, and hair loss. This is because in its zeal to attack cancer cells, chemo also kills healthy cells.

(more…)

How DNA-encoded Libraries Boost Drug Discovery

Posted on October 7th, 2020 in Pharma R&D

DNA-encoded libraries (DELs) have been gaining a lot of traction in hit finding and drug discovery in recent years. Regarded by some as a truly revolutionary advance in chemistry, a DEL is a mixture of millions of small molecules in which each molecule is conjugated to a DNA-oligomer that encodes its chemical structure. The mixture can be stored in a simple test tube.

(more…)

Extracting Relevant Chemical Information from Patents with Machine Learning

Posted on October 5th, 2020 in Chemistry

New chemical compounds and reactions are often introduced to the world – and with little fanfare – through patents. It may be years after the patent has been filed before these compounds are published in scholarly journals, and even then it is only a small share of them that are published at all. As a result, it can be easy for these compounds to remain unknown to researchers who may be very interested in them.

(more…)

Predicting Cancer Drug Combinations That Work

Posted on August 6th, 2020 in Pharma R&D

Dr. Bart Westerman is a Group Leader and Assistant Professor at the VU University Medical Center in Amsterdam. There he heads research projects in neuro-oncology, as well as in the use of bioinformatics to tackle complex, multidimensional questions to transform cancer therapy decision-making and management. He and his colleagues recently published a cancer drug atlas that predicts synergistic combination therapies for cancer.

(more…)

  1. 1
  2. 2
  3. 3
  4. 8